LENZ Therapeutics (LENZ) Set to Announce Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is scheduled to be announcing its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. On average, analysts expect LENZ Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Trading Up 0.7 %

NASDAQ LENZ traded up $0.19 during trading on Tuesday, reaching $28.62. 81,522 shares of the company’s stock were exchanged, compared to its average volume of 134,330. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $31.00. The company’s fifty day simple moving average is $24.16 and its 200-day simple moving average is $20.82.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Raymond James started coverage on LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 target price for the company. Piper Sandler reiterated an “overweight” rating and issued a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. HC Wainwright initiated coverage on LENZ Therapeutics in a report on Monday, August 12th. They set a “buy” rating and a $38.00 target price on the stock. Finally, William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, LENZ Therapeutics has a consensus rating of “Buy” and an average target price of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.